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Robin Spiller, Editor
A Crohn’s disease patient with
pustules and fever
CLINICAL PRESENTATION
A woman in her thirties was recently diagnosed with Crohn’s
disease involving the oesophagus and colon. In addition, she had
aphtous mouth ulcers and peri-anal fistulas. She was success-
fully treated with steroids, 6-mercaptopurine (6-MP) and
infliximab. Two months later she presented with a flare-up of
disease and recurrence of the mouth ulcers. In addition, she had
fever up to 39uC, arthralgias and pustules on her back and
buttocks (fig 1). Blood tests revealed an erythrocyte sedimenta-
tion rate (ESR) of 44 mm/h, C-reactive protein (CRP) of 65 mg/l
and leucocytes of 136109/litre. Blood, urinary and stool cultures
as well as chest x ray did not reveal an infectious cause of the fever.
Withdrawal of the 6-MP had no effect on the fever. The fistulas
were not active upon magnetic resonance imaging (MRI). Joints
were tender but not swollen. Dermatological investigation
showed multiple purulent pustules. Cultures of the pustules
were negative whereas skin biopsy showed a predominantly
neutrophilic infiltrate of the dermis with admixture of histiocytes
and lymphocytes.
QUESTIONS
(1) What skin lesions are shown here?
(2) What is the diagnosis?
See page 1564 for the answer
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Figure 1 Pustular skin lesions (A); detail (B).
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ANSWER
From the question on page 1537
The patient was diagnosed with the bowel-associated derma-
tosis arthritis syndrome (BADAS). It was first described in
patients undergoing ileojejunal bypass surgery for morbid
obesity1 and since then in various other intestinal disorders,2
including occasionally in inflammatory bowel disease (IBD).3 4
Clinical presentation is heterogeneous, but is usually charac-
terised by sterile pustular skin lesions, fever, diarrhoea, arthritis,
and eye inflammation. The symptoms generally disappear once
the intestinal manifestations ameliorate. Skin lesions character-
istically consist of small erythematous lesions with a perivas-
cular neutrophilic infiltrate and dermal oedema (fig 1).
Histological features however are non-specific and clinical
history is essential for a correct diagnosis. The aetiology is
believed to be related to bacterial overgrowth leading to the
formation and deposition in skin and synovia of circulating
immune complexes and subsequent activation of neutrophilic
granulocytes.5
As in this patient, BADAS usually responds well to high-dose
steroids. It may also respond to antibiotics. Antibiotics have
been reported to be beneficial in up to 50% of patients with
BADAS after bypass surgery, although the response has been
inconsistent.6 As far as we know, the therapeutic effect of
antibiotics in patients with IBD and BADAS has not been
evaluated. Since the pathophysiology is presumed to be similar
in both disease entities, a course of antibiotics could be tried in
patients with IBD and BADAS. The patient presented here had
no clinical manifestations that might predispose her to bacterial
overgrowth; however, she was not formally tested to exclude
this possibility. Given the severity of her symptoms, treatment
was initiated with high-dose corticosteroids (40 mg prednison/
day). The fever disappeared instantly while the skin manifesta-
tions completely resolved within 1 week. Steroids were slowly
tapered and symptoms have not recurred since then.
In conclusion, it is important to consider the possibility of a
BADAS in patients with IBD who have unexplained fever and
skin lesions because treatment may lead to prompt resolution of
the symptoms and prevent an exhaustive search for other causes
of fever.
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Figure 1 Haematoxylin & eosin stained
photomicrograph of the dermis and
epidermis demonstrating a perivascular
and perifollicular neutrophilic infiltrate.
Magnification: (A) 62.5; (B) 620.
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